Skip to content

Study · Not a test of the peptide alone · 2020

3 results

Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.

Herrera Comoglio R, Vidal Guitart X

International journal of clinical practice17 Jun 2020Cited by 8 (Europe PMC)

PMID32452094 (opens in a new tab)DOI10.1111/ijcp.13553 (opens in a new tab)PepBankPUB-32452094
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) were linked to lower all-cause mortality in observational cohorts.

    In plain wordsIn adults with type 2 diabetes, people on GLP-1 drugs, including liraglutide, were linked to lower death rates in observational studies.

    Peptide
    Liraglutide
    Outcome
    DecreaseAll-cause mortality, pooled HR
    Study

    n: not reported in source

    Comparator
    No exposure or other antidiabetic drugs
    Outcome group
    Mortality · Cardiovascular

    Measurements

    Pooled HR
    0.63 HR
    all-cause mortality

    Source sentences

    Summary
    Excluding two studies because of temporal bias, we obtained pooled estimates for all-cause mortality: HR 0.63 (0.44-0.89)
    1 context sentence
    Summary · context
    Sixteen studies included 285,436 T2DM patients exposed to GLP-1 RAs (exenatide bid, liraglutide, lixisenatide, long-acting exenatide), n ranged from 219 to 160,803 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) were linked to fewer cardiovascular outcomes in observational cohorts.

    In plain wordsIn adults with type 2 diabetes, people on GLP-1 drugs, including liraglutide, were linked to fewer heart and blood vessel events in observational studies.

    Peptide
    Liraglutide
    Outcome
    DecreaseCardiovascular outcomes, pooled HR
    Study

    n: not reported in source

    Comparator
    No exposure or other antidiabetic drugs
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Pooled HR
    0.84 HR
    cardiovascular outcomes

    Source sentences

    Summary
    CV outcomes HR 0.84 (0.75-0.94)
    1 context sentence
    Summary · context
    Sixteen studies included 285,436 T2DM patients exposed to GLP-1 RAs (exenatide bid, liraglutide, lixisenatide, long-acting exenatide), n ranged from 219 to 160,803 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) were neutral for hospitalisation for heart failure in observational cohorts.

    In plain wordsIn adults with type 2 diabetes, people on GLP-1 drugs, including liraglutide, showed no clear link with hospital stays for heart failure in observational studies.

    Peptide
    Liraglutide
    Outcome
    No significant changeHospitalisation for heart failure, pooled HR
    Study

    n: not reported in source

    Comparator
    No exposure or other antidiabetic drugs
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Pooled HR
    0.94 HR
    hospitalisation for heart failure

    Source sentences

    Summary
    HHF; HR 0.94 (0.78-1.14)
    1 context sentence
    Summary · context
    Sixteen studies included 285,436 T2DM patients exposed to GLP-1 RAs (exenatide bid, liraglutide, lixisenatide, long-acting exenatide), n ranged from 219 to 160,803 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.